We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) closed the most recent trading day at $0.78, moving -2.32% from the previous trading session. This change lagged the S&P 500's 0.79% gain on the day. Meanwhile, the Dow experienced a rise of 0.26%, and the technology-dominated Nasdaq saw an increase of 1.52%.
Shares of the company witnessed a loss of 44.9% over the previous month, trailing the performance of the Medical sector with its gain of 7.53%, and the S&P 500's loss of 1.82%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.1, up 58.33% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $1.39 million, reflecting a 363.33% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.34 per share and revenue of $8.03 million, indicating changes of -30.77% and +293.77%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 6.32% lower within the past month. At present, Humacyte, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 159, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA - Free Report) closed the most recent trading day at $0.78, moving -2.32% from the previous trading session. This change lagged the S&P 500's 0.79% gain on the day. Meanwhile, the Dow experienced a rise of 0.26%, and the technology-dominated Nasdaq saw an increase of 1.52%.
Shares of the company witnessed a loss of 44.9% over the previous month, trailing the performance of the Medical sector with its gain of 7.53%, and the S&P 500's loss of 1.82%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.1, up 58.33% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $1.39 million, reflecting a 363.33% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.34 per share and revenue of $8.03 million, indicating changes of -30.77% and +293.77%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 6.32% lower within the past month. At present, Humacyte, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 159, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.